The advantages of modified versions over conventional dosage forms are encouraging several companies to focus on developing modified versions of the existing corticosteroid preparations, and oral corticosteroids.
LONDON--(BUSINESS WIRE)-- The advantages of modified versions over conventional dosage forms are encouraging several companies to focus on developing modified versions of the existing corticosteroid preparations, and oral corticosteroids. For instance, the prolonged action dosage forms increase the drug absorption rate and maximize the bioavailability of the drug with a minimum dose. Thus, the reformulation of drugs is expected to fuel the growth of Addison’s disease therapeutics market during the forecast period. Furthermore, this industry research report also presents a competitive analysis of the market by product (oral drugs and parenteral drugs) and geography (Asia, Europe, North America, and ROW).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190710005265/en/
Technavio has released a new market research report on the global Addison’s disease therapeutics market from 2019-2023. (Graphic: Business Wire)
Competitive vendor landscape
The global Addison’s disease therapeutics market is highly competitive with major vendors such as Bristol-Myers Squibb Company, Merck & Co. Inc., Novartis AG, Pfizer Inc., and Takeda Pharmaceutical Company Limited, competing based on price, quality, and market presence.
“The popularity of regenerative therapies increasing significantly, owing to the minimal side effects associated with the therapy. Thus, many research institutions and companies are increasingly focusing on developing regenerative therapies for the treatment of Addison’s disease. Although the approach is still in the pre-clinical development stages, it is expected to be a suitable treatment for Addison’s disease once approved,” says a senior analyst at Technavio.
Top five Addison’s disease therapeutics market vendors
Bristol-Myers Squibb Company is a leading manufacturer of biopharmaceutical products. The company engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sales of innovative medicines for the treatment of serious diseases. The company offers FLORINEF, which is indicated as partial replacement therapy for the treatment of patients with primary and secondary adrenocortical insufficiency.
Merck & Co., Inc. is one of the leading pharmaceutical companies that discover, develop, manufacture, and sell human health pharmaceuticals and vaccine products. The company currently offers three approved therapies for Addison’s disease that include DECADRON, Astonin H, and Lonikan.
Novartis AG owns and operates businesses in three major segments that include innovative medicine - Sandoz and Alcon. The company offers methylprednisolone acetate, which is indicated in combination with synthetic mineralocorticoid analogs for the treatment of patients with Addison’s disease.
Pfizer Inc. is one of the largest players in the innovative health segment, which includes six prime therapeutic areas, internal medicine, vaccines, oncology, inflammation and immunology, rare diseases, and consumer health. The company’s offerings in the market include SOLU-CORTEF, MEDROL, A-METHAPRED, and Cortef.
Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is one of the established companies in the pharmaceutical business. The company focuses on the discovery, manufacturing, and commercialization of pharmaceutical products for various indications. The company offers Plenadren, which is a modified-release hydrocortisone preparation indicated for the treatment of patients with primary and secondary adrenal insufficiency.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report, including the market size and forecast, drivers, challenges, trends, and more.
Browse Related Reports:
- Global Parasitic Diseases Therapeutics Market 2019-2023 - The market research study identifies Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Pfizer Inc., Sanaria Inc as the leading players in the global parasitic diseases therapeutics market.
- Global Von Willebrand Disease Therapeutics Market 2019-2023 - The market research study identifies Baxter, CSL, Grifols, Octapharma, and Shire as the leading players in the global Von Willebrand disease therapeutics market.
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190710005265/en/
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
technavio.com
media@technavio.com
Source: Technavio Research
Smart Multimedia Gallery
Technavio has released a new market research report on the global Addison’s disease therapeutics market from 2019-2023. (Graphic: Business Wire)
View this news release and multimedia online at:
http://www.businesswire.com/news/home/20190710005265/en
